{"entity":{"id":"nrg1","kind":"target","name":"NRG1","aka":["neuregulin 1","Pro-neuregulin-1, membrane-bound isoform","NRG1-IT2"],"tldr":"NRG1 (Pro-neuregulin-1, membrane-bound isoform) is a protein on the cell surface. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and an antigen, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Breast cancer and 5 more.","summary":"Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumour cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart.\n\nCIViC holds 9 clinical evidence items and 0 assertions across 3 variants, naming Lapatinib, Afatinib, Gefitinib and Erlotinib and others. Open Targets scores its association with cancer at 0.83 (direct and indirect evidence; datatypes affected pathway 0.92, literature 0.99, genetic association 0.70, somatic mutation 0.86, animal model 0.57). IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma, Papillary Renal Cell Carcinoma, Stomach Adenocarcinoma. In OnCo, 1 product record names it (Zenocutuzumab).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:7997","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7997"},{"label":"UniProt Q02297","url":"https://www.uniprot.org/uniprotkb/Q02297/entry"},{"label":"NCBI Gene 3084","url":"https://www.ncbi.nlm.nih.gov/gene/3084"},{"label":"Ensembl ENSG00000157168","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157168"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["lung-cancer","thyroid","breast-cancer","colorectal","ovarian","head-and-neck","gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["zenocutuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02912949"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 12 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 9 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene; a membrane or secreted protein (UniProt keywords) that 1 antibody-based OnCo product name. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"NRG1","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner","antigen"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:7997","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7997","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q02297","url":"https://www.uniprot.org/uniprotkb/Q02297/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene NRG1","url":"https://civicdb.org/features/2593","note":"9 evidence items, 0 assertions, 3 variants; diseases: Lung Non-small Cell Carcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer, Head And Neck Squamous Cell Carcinoma and 1 more (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000157168","url":"https://platform.opentargets.org/target/ENSG00000157168/associations","note":"association with cancer (MONDO_0004992) 0.83; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.67, gastric cancer 0.54, oesophageal cancer 0.51, thyroid cancer 0.64, neuroendocrine neoplasm 0.52, skin cancer 0.52 (GraphQL API, CC0)"},{"label":"IntOGen NRG1","url":"https://www.intogen.org/search?gene=NRG1","note":"driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:7997","ensembl":"ENSG00000157168","uniprot":"Q02297","entrez":"3084","biology":"Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumour cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart. Isoform 10 may play a role in motor and sensory neuron development. Binds to ERBB4. Binds to ERBB3. Location: Cell membrane; Secreted; Nucleus; Membrane (UniProt). Locus 8p12 (HGNC).","whereFound":["Lung cancer: Open Targets association 0.68 with lung cancer (MONDO_0008903)","Thyroid cancer: Open Targets association 0.64 with thyroid cancer (MONDO_0002108)","Breast cancer: Open Targets association 0.58 with breast cancer (MONDO_0007254); CIViC evidence names this disease","Colorectal cancer: CIViC evidence names this disease","Ovarian cancer: CIViC evidence names this disease","Head and neck squamous cell carcinoma: CIViC evidence names this disease"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/nrg1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"drug":[{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/"}],"trial":[{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/"}]}}